Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. - Wikidata - awgldk - TriplyDB

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

http://www.wikidata.org/entity/Q35780973

about

Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6 Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status Progressive degeneration of human neural stem cells caused by pathogenic LRRK2 Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2 Phosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7 A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications The role of the LRRK2 gene in Parkinsonism Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase.Selective Aurora Kinase Inhibitors Identified Using a Taxol-Induced Checkpoint Sensitivity Screen X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations Parkinson's disease and immune system: is the culprit LRRKing in the periphery?LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives Inhibition of LRRK2 kinase activity stimulates macroautophagy The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias Regulation of LRRK2 expression points to a functional role in human monocyte maturation mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1 Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.

P2860

Q21131229-A93DA647-700E-4919-A861-9DBBEF46CF21 Q24294458-43AB1422-64DC-46F6-B708-7D3EF1FF7ABD Q24296778-FF76E517-A2E8-4A33-B323-B84B44C79374 Q24298093-483ADB39-6461-450E-9E3F-B437D78F4CEA Q24298891-DB27B6B1-F9A9-4FB5-B2BB-C7E1C448CB3F Q24299578-FCA90FF8-ABF2-4FAF-BD9B-B08842223F4F Q24300605-3561F57D-5C69-4DE2-ACEA-C7C973E7435E Q24301070-EF6672F5-0596-44FF-BFF8-88C322A49831 Q24307004-52650680-F2AF-4248-8490-1D3137DFD60F Q24307742-27D26800-5A9B-420B-BEC5-601351187E20 Q24309417-F853A8CD-0699-4547-8090-EC98F28B2450 Q24310126-250A1113-644C-4170-A592-417EC200C777 Q24317158-2222E15F-5417-457D-B883-4DB29779C262 Q24318474-3731D63E-4016-457A-90BD-E8C2D7BADDD5 Q24323196-52150311-9DA9-43D5-BF7A-419A1CF671D5 Q24324345-3E175A5A-C24A-4E33-ACDE-7D5B4F58B351 Q24339009-6D408860-4939-4EEB-B55E-BEC9E7B89835 Q26746897-3C3D9F3B-ED74-42DA-BFDA-E5DEE4BA38C1 Q26827527-B9BC6EB4-326A-4AB9-8B2B-5B032540AE3D Q26853537-358BD347-44B7-42F6-8D89-A0FB61974D14 Q27007413-B8904577-B4C4-446B-934A-1161CFFE0E29 Q27013695-CE0BC9BB-304F-4097-A3B9-8AD4CDA83043 Q27023749-502C4F51-E77F-4F73-9377-2907E7B2C876 Q27026262-A2193BEB-A60C-477E-B063-B90FB7C7641F Q27312569-EE9FEE6A-BD7B-414F-87AA-019B2DBF9DCC Q27315276-8EAD4473-A079-44D0-9B54-791FC2EDB6E6 Q27322966-55D9EE11-007B-4B3E-9359-5FAC61D14CF4 Q27674986-FA599F61-C9B8-4083-8890-F0D960A8B2C4 Q27678046-DFA1FD1E-35FE-47D2-BFC2-D47053198A4B Q27681111-005554FE-957F-4BEF-95EA-C7AE33784A31 Q27687171-B1237204-BF85-40BD-A387-CF7CB2A7F997 Q28078899-8D2687C7-2961-4B2F-9149-2305F7B8ED2B Q28118311-CD10461A-CE75-45C5-B832-E2074406FE49 Q28480459-E11FDC8F-4D59-490E-BEAD-92C8A0C5966B Q28482925-2F60CFD1-3272-423E-B76E-29D7BF802475 Q28545100-C5BE7AA1-55BF-4542-9EB3-B2219B779C9C Q28602836-359C9E4C-92CF-42D6-ABF0-E998A279E1B8 Q28743193-A44B6798-3315-4225-B9AC-C793A180A2B6 Q28822211-1FC0CBE8-0144-4920-A250-3F79B9313BB2 Q30384542-6AACE56C-91CE-40C5-9DC2-A5CE2687F7A9

P2860

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

http://www.wikidata.org/entity/Q35780973

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

@ast

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

@en

type

label

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

@ast

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

@en

prefLabel

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

@ast

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

@en

P1433

Q35780973-F1DE26F3-24C6-45C6-8498-C1401A4D10A8

P1476

Q35780973-2C513BB1-0FC0-4BFF-9153-63B21CDB013F

P2093

Q35780973-03E9EE47-C9EB-4834-9EA8-6D5FB24F0340

Q35780973-3650F110-5290-4849-B6E3-3775E9469F33

Q35780973-3AF35EFA-C571-4337-9FA2-3A8A0D8A6C0B

Q35780973-733A2583-EDB2-4C76-983F-A516F2E34D1C

Q35780973-77A2901C-BF93-4C5B-A425-75E118C9A895

Q35780973-8D14A988-E52C-4854-A5C0-25AE4A58B8F0

P2860

Q35780973-0436BC0D-4BF7-485C-9353-7D5C93D6075F

Q35780973-180CC49D-B888-4524-9FDA-AE99EDD00F5B

Q35780973-2B88ED03-6361-4F6F-A492-C692B316DC60

Q35780973-30197BA6-1CEA-4785-839E-7D4A77781EF9

Q35780973-45798BE0-2AA0-4386-82A1-075279ECB866

Q35780973-5F9E696D-6005-42E7-BF0C-1643C250F08A

Q35780973-6579A076-1EE9-4F03-97E7-DF9F29514C13

Q35780973-74351C46-6487-4278-9155-6046C21F7093

Q35780973-76AD70B1-CA21-4A6B-B2DE-4759C45E0304

Q35780973-7B329327-D567-4313-8B0B-E82FFCE8E29E

P2888

Q35780973-E160E5FC-2A24-4712-B67B-B7A936FAC8CE

P304

Q35780973-9FBF4BF7-8135-4221-9069-C0215C4F7752

P31

Q35780973-FCBB3D1D-06F8-4F6B-8993-C6629367B847

P356

Q35780973-F8B8087D-F154-467C-B06E-159E6C10F0F1

P433

Q35780973-8B022702-B9CB-4858-87F1-03FDEF0EEB91

P478

Q35780973-C1D4E050-7B0E-450C-B9D2-CE8AA61BC6F0

P50

Q35780973-4855061D-B033-4C31-A4C0-FD7B59E63256

Q35780973-83C7CB65-FD2B-440F-9338-8C93067DCFD1

Q35780973-A108AF20-911B-4022-8C45-F6F2A4F6B445

Q35780973-E75EC131-B2B1-4A2C-A631-D477A3AEB4CD

Q35780973-E786B788-A470-4BA6-84FA-B45B9891681A

P577

Q35780973-99E0E78D-D26B-4096-AF8B-A076078217CE

P5875

Q35780973-B9ECAF11-C586-482B-AEC5-79190674902B

P698

Q35780973-E212D907-24B3-4280-B3BC-7E257BA2ABA1

P921

Q35780973-DCF118FC-B30E-4444-8E87-4146CD3DFE81

Q35780973-EF30881B-E46C-4995-BAEA-2C031FD53CDB

P932

Q35780973-8AA4C555-6265-4DE3-80B4-63AA1750F8D4

P356

P1433

Nature Chemical Biology

P1476

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

@en

P2093

Jiing-Dwan Lee

http://www.w3.org/2001/XMLSchema#string

Matthew P Patricelli

http://www.w3.org/2001/XMLSchema#string

Nathanael S Gray

http://www.w3.org/2001/XMLSchema#string

Paul Davies

http://www.w3.org/2001/XMLSchema#string

Tyzoon K Nomanbhoy

http://www.w3.org/2001/XMLSchema#string

Xianming Deng

http://www.w3.org/2001/XMLSchema#string

P2860

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization

The selectivity of protein kinase inhibitors: a further update

LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

A quantitative analysis of kinase inhibitor selectivity

Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

A small molecule-kinase interaction map for clinical kinase inhibitors

P2888

P304

203-205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCHEMBIO.538

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Alan R. Prescott

P577

2011-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50290128

http://www.w3.org/2001/XMLSchema#string

P698

21378983

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3287420

http://www.w3.org/2001/XMLSchema#string